Approaching the post-antibiotic era: phage therapy current practices and future horizons
mBio · 2026
DOI: 10.1128/mbio.03254-25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift mBio, 2026. Verfasst von Madison E Stellfox und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Phage Therapy, Bacterial Infections, Bacteriophages. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.
Abstract (Originalsprache)
Bacteriophages (phages) are the viral predators of bacteria. Their ability to infect and kill bacterial strains has been harnessed for use in clinical practice for more than a century, but their development stalled for decades in many regions. Now, in the face of increasingly complex bacterial infections that fail conventional therapeutic options, and the growing global threat of antibiotic resistance, interest in phage therapy has resurged. Data evaluating the impact of phage therapy via clinical trials are steadily increasing, but remain sparse. Yet, an ever-growing number of case reports and case series highlights the potential of phage therapy to make a positive impact in the battle against antimicrobial resistance and difficult-to-treat bacterial infections. In this review, we summarize the available data describing the clinical utility of phage therapy, highlight infectious indications where phage therapy shows strong potential, and call attention to disease states where the benefits of phage therapy, as it is practiced today, are less certain. Furthermore, we note areas where there is a crucial need for additional research and propose how scientists and clinicians can work together to design and carry out the preclinical and clinical studies that will take phage therapy into its next century.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Pittsburgh Phage Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Center for Evolutionary Biology and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Bethel Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Madison E Stellfox, Ryan K Shields, Kenneth L Urish, Ghady Haidar, Daria Van Tyne
Förderung
- NIAMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- Cumberland Pharmaceuticals
- Cystic Fibrosis Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Stellfox, M. E., Massey, J., Hughes Kramer, K., Shields, R. K., Urish, K. L., Haidar, G., & Van Tyne, D. (2026). Approaching the post-antibiotic era: phage therapy current practices and future horizons. mBio. https://doi.org/10.1128/mbio.03254-25
Vancouver
Stellfox ME, Massey J, Hughes Kramer K, Shields RK, Urish KL, Haidar G, et al. Approaching the post-antibiotic era: phage therapy current practices and future horizons. mBio. 2026. doi:10.1128/mbio.03254-25
BibTeX
@article{Stellfox2026,
author = {Stellfox, Madison E and Massey, Justin and Hughes Kramer, Kailey and Shields, Ryan K and Urish, Kenneth L and Haidar, Ghady and Van Tyne, Daria},
title = {Approaching the post-antibiotic era: phage therapy current practices and future horizons},
journal = {mBio},
year = {2026},
doi = {10.1128/mbio.03254-25}
}
EUVIMED